Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label IV vedolizumab extension study in pediatric ulcerative colitis or Crohn's disease
MOH_2017-09-18_000649Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Not reported. Started Sep 2017; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2017-09-18_000649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-18_000649.